« Return to News | Ethics/Regulatory

Coast IRB to Close in Wake of GAO Investigation

Monday, April 27, 2009 09:31 AM

Coast IRB, the institutional review board (IRB) that was the target of an undercover investigation by the Government Accountability Office (GAO), is closing its doors, according to reports published last week.

The FDA had issued a warning letter to Coast earlier this month, outlining five “serious violations” to FDA laws and regulations and questioning the IRB’s ability to protect human subjects participating in clinical trials. In response to the letter, Coast voluntarily suspended the approval of new studies as well as the recruitment of new patients for ongoing studies and planned to issue a corrective action plan to the FDA by the end of April.

Plans changed last week, however, when the IRB issued a statement saying it was closing and would work to transfer its ongoing trials (about 300 active trials, according to reports) to other accredited IRBs.

The FDA’s warning letter stemmed from an undercover investigation conducted by the Government Accountability Office (GAO) between January 2008 and March 2009 to test whether IRBs adequately review studies submitted for their approval. Coast was one of three IRBs selected by the GAO to receive a research study for approval for a “fictitious medical device with no proven test history and bogus specifications,” according to the GAO, and it was the only IRB to approve the research protocol.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.